Healthcare of Ontario Pension Plan Trust Fund raised its holdings in Quest Diagnostics Incorporated (NYSE:DGX – Free Report) by 1.5% during the 1st quarter, HoldingsChannel.com reports. The fund owned 170,912 shares of the medical research company’s stock after acquiring an additional 2,515 shares during the quarter. Healthcare of Ontario Pension Plan Trust Fund’s holdings in Quest Diagnostics were worth $33,495,000 at the end of the most recent reporting period.
Other large investors have also recently modified their holdings of the company. Assenagon Asset Management S.A. boosted its holdings in shares of Quest Diagnostics by 346.5% in the 4th quarter. Assenagon Asset Management S.A. now owns 24,949 shares of the medical research company’s stock worth $4,329,000 after purchasing an additional 19,361 shares in the last quarter. Davis Selected Advisers raised its holdings in shares of Quest Diagnostics by 16.8% during the 4th quarter. Davis Selected Advisers now owns 1,589,883 shares of the medical research company’s stock valued at $275,895,000 after buying an additional 228,271 shares in the last quarter. Capital Management Associates Inc purchased a new position in shares of Quest Diagnostics during the 4th quarter valued at about $1,024,000. ANTIPODES PARTNERS Ltd lifted its position in Quest Diagnostics by 178.7% in the 4th quarter. ANTIPODES PARTNERS Ltd now owns 171,987 shares of the medical research company’s stock worth $29,847,000 after buying an additional 110,280 shares during the last quarter. Finally, Advisors Capital Management LLC lifted its position in Quest Diagnostics by 5.4% in the 4th quarter. Advisors Capital Management LLC now owns 313,838 shares of the medical research company’s stock worth $54,460,000 after buying an additional 16,194 shares during the last quarter. Institutional investors own 88.06% of the company’s stock.
Insider Buying and Selling at Quest Diagnostics
In other Quest Diagnostics news, CEO J. E. Davis sold 10,000 shares of the stock in a transaction on Monday, June 1st. The shares were sold at an average price of $194.14, for a total transaction of $1,941,400.00. Following the completion of the sale, the chief executive officer owned 132,423 shares of the company’s stock, valued at $25,708,601.22. This represents a 7.02% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Karthik Kuppusamy sold 8,147 shares of the firm’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $200.00, for a total transaction of $1,629,400.00. Following the completion of the sale, the senior vice president directly owned 13,510 shares in the company, valued at approximately $2,702,000. This trade represents a 37.62% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.88% of the stock is owned by insiders.
Quest Diagnostics Trading Up 0.1%
Quest Diagnostics (NYSE:DGX – Get Free Report) last announced its quarterly earnings results on Thursday, July 23rd. The medical research company reported $3.12 EPS for the quarter, topping analysts’ consensus estimates of $2.82 by $0.30. Quest Diagnostics had a return on equity of 16.01% and a net margin of 9.18%.The business had revenue of $3.04 billion for the quarter, compared to analysts’ expectations of $2.97 billion. During the same period in the previous year, the firm earned $2.62 EPS. The business’s quarterly revenue was up 10.2% on a year-over-year basis. Quest Diagnostics has set its FY 2026 guidance at 11.050-11.250 EPS. As a group, sell-side analysts anticipate that Quest Diagnostics Incorporated will post 11.17 earnings per share for the current year.
Quest Diagnostics Announces Dividend
The company also recently announced a quarterly dividend, which was paid on Wednesday, July 22nd. Investors of record on Wednesday, July 8th were paid a $0.86 dividend. This represents a $3.44 annualized dividend and a dividend yield of 1.5%. The ex-dividend date of this dividend was Wednesday, July 8th. Quest Diagnostics’s payout ratio is presently 36.52%.
Quest Diagnostics News Summary
Here are the key news stories impacting Quest Diagnostics this week:
- Positive Sentiment: Quest Diagnostics posted Q2 results that beat Wall Street expectations on both revenue and earnings, helped by stronger demand for routine diagnostic and preventive testing. The company also raised its full-year 2026 outlook, which investors are reading as evidence that growth is holding up well. Article: Quest Diagnostics Reports Second Quarter 2026 Financial Results; Raises Revenue and EPS Guidance for Full Year 2026
- Positive Sentiment: Mizuho raised its price target on DGX to $260 and kept an outperform rating, signaling confidence that the company can still outperform from here. Article: Quest Diagnostics price target raised by Mizuho
- Positive Sentiment: Truist also lifted its target to $250, while Robert W. Baird increased its target to $255, reflecting continued analyst optimism after the earnings beat and raised guidance. Article: Quest Diagnostics price target raised by Truist Financial Corporation
- Neutral Sentiment: Several market commentary pieces highlighted DGX as a momentum stock and noted the shares recently reached a 52-week high. That supports bullish sentiment, but these articles are mostly follow-up coverage rather than a new fundamental catalyst. Article: Are You Looking for a Top Momentum Pick? Why Quest Diagnostics (DGX) Is a Great Choice
Analyst Ratings Changes
A number of research analysts have commented on DGX shares. Wall Street Zen cut shares of Quest Diagnostics from a “buy” rating to a “hold” rating in a research report on Monday, July 20th. Jefferies Financial Group restated a “buy” rating and issued a $245.00 price objective on shares of Quest Diagnostics in a report on Thursday. Mizuho upped their price objective on shares of Quest Diagnostics from $235.00 to $260.00 and gave the company an “outperform” rating in a research note on Friday. Robert W. Baird increased their target price on shares of Quest Diagnostics from $236.00 to $255.00 and gave the company a “neutral” rating in a report on Friday. Finally, Barclays lifted their target price on shares of Quest Diagnostics from $230.00 to $250.00 and gave the stock an “overweight” rating in a research report on Thursday. Six research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $231.73.
View Our Latest Stock Report on Quest Diagnostics
Quest Diagnostics Profile
Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.
Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.
Read More
- Five stocks we like better than Quest Diagnostics
- RTX and Lockheed Earnings: Can Strong Guidance Reset the Defense Trade?
- These 4 Earnings Reports Expose the Market’s Growing Economic Divide
- Broadcom May Be the Biggest Winner From Alphabet’s Earnings
- Volatility Is Back and These 3 Market Tollbooths Are Best Positioned to Profit
Want to see what other hedge funds are holding DGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Quest Diagnostics Incorporated (NYSE:DGX – Free Report).
Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
